The dCAR-engineered T cell cytotoxicity was effectively controlled with cognate tumor cells (AsPC-1) expressing CEA and MSLN, thereby mitigating “on-target, off-tumor” toxicity and improving the safety of T cell therapy. This evidence concerns the gene CEACAM5 and neoplasm.